Tango Therapeutics, Inc.

EX-99.1 · d158334dex991.htm

EX-99.1
 2
 d158334dex991.htm
 EX-99.1

 Exhibit 99.1

 Tango Therapeutics Announces Combination of Vopimetostat and Daraxonrasib Demonstrated 92% Objective
Response Rate in Pancreatic Cancer
 Initial data from ongoing Phase 1/2 trial in patients with second and third line PDAC treated
with vopimetostat and daraxonrasib showed 6-month PFS rate of 90% (median PFS not yet reached) suggesting durability of clinical benefit

 Vopimetostat combinations with Revolution Medicines’ RAS(ON) inhibitors daraxonrasib or zoldonrasib were generally well-tolerated

 Data support rapid advancement of vopimetostat plus daraxonrasib combination into Phase 3 development in first-line MTAP deleted
pancreatic cancer
 Conference call today, June 8, 2026, at 8:00am ET

 BOSTON, June 8, 2026 (GLOBE NEWSWIRE) — Tango Therapeutics, Inc. (NASDAQ: TNGX), a clinical-stage biotechnology company committed to discovering
and delivering the next generation of precision cancer medicines, today announced positive initial data from its ongoing Phase 1/2 study of vopimetostat, an investigational PRMT5 inhibitor with first- and best-in-class potential, in combination with Revolution Medicines’ RAS(ON) inhibitors in patients with MTAP-deleted and RAS-mutant metastatic pancreatic ductal
adenocarcinoma (PDAC).
 “In the first reported data from the clinical combinations of our PRMT5 inhibitor vopimetostat and RAS(ON) inhibitors, we
saw extremely encouraging early results, with 92% of patients with PDAC in the vopimetostat plus daraxonrasib arm achieving an objective response, supporting the preclinical data showing synergistic activity of PRMT5 + RAS inhibition,” said
Malte Peters, MD, Chief Executive Officer of Tango Therapeutics. “Equally important, we are seeing encouraging signals of durability, with 90% of PDAC patients still progression free at 6 months of follow up. In addition, both combinations
were generally well tolerated. Our primary focus is now to bring forward the PRMT5 plus RAS inhibitor combination approach in pancreatic cancer, while also looking toward important upcoming data readouts for vopimetostat single agent in lung cancer
and TNG456 in GBM which we believe represents significant long-term opportunity for our company.”
 Dr. Peters continued, “These
compelling results reinforce our belief that a vopimetostat-based combination with RAS inhibitors may be a path to a chemotherapy-free option for patients with MTAP-deleted pancreatic cancer. Given these data, we intend to prioritize advancement of
the vopimetostat plus daraxonrasib combination into Phase 3 development in first-line, MTAP- deleted pancreatic cancer.”
 “Pancreatic cancer
remains a largely intractable disease and an area where patients desperately need new therapies,” said Brian Wolpin, MD, Director of the Hale Family Center for Pancreatic Cancer Research, Dana-Farber Cancer Institute. “In the front-line
setting, chemotherapy has long been the standard of care, yet it presents significant tolerability challenges and overall limited efficacy against this aggressive disease. Building on the monotherapy activity already shown by these investigational
PRMT5 and RAS(ON) targeted therapies, these early combination data demonstrated the potential to meaningfully reshape how we treat this disease with a precision-guided, chemotherapy-free approach.”

 Topline Phase 1/2 Clinical Data Highlights

 As of a data cutoff date of May 28, 2026, 59 patients with previously treated MTAP-deleted and RAS-mutant
pancreatic ductal adenocarcinoma (PDAC) or non-small cell lung cancer (NSCLC) were treated with a vopimetostat-based combination with either daraxonrasib (n=20 PDAC; n=5 NSCLC) or zoldonrasib (n=34 PDAC). All
patients had advanced disease, including 70% with liver metastases in the daraxonrasib PDAC arm and 77% with liver metastases in the zoldonrasib arm, and were generally heavily pre-treated, with more than half
receiving the combinations as third-line treatment.
 Vopimetostat plus daraxonrasib combination

 In the vopimetostat plus daraxonrasib dose escalation arm, patients received either vopimetostat 200 mg or 250 mg once daily (QD) plus daraxonrasib 100 mg QD.
As of the data cutoff, 12 patients with PDAC and 3 patients with NSCLC were response evaluable with at least 14 weeks of follow up.
 Data highlights
include:

 •

 PDAC:

 •

 92% objective response rate (ORR) (11/12; 9 of 11 responses confirmed)

 •

 90% 6-month PFS rate

 •

 100% disease control rate (DCR)

 •

 NSCLC: 100% ORR, 3 of 3 responses confirmed

 •

 The vopimetostat + daraxonrasib was generally well tolerated across all dose levels with no new safety signals
observed

 •

 Most adverse events were Grade 1 or 2 in severity. The most common treatment-related adverse events (TRAEs) were
rash, stomatitis/mucositis and diarrhea.

 •

 There were no related Grade 4 or 5 adverse events

 •

 There were no dose-limiting toxicities (DLTs) at dose level 1 (vopimetostat 200 mg/daraxonrasib 100 mg). Three
DLTs were reported in two patients at dose level 2 (vopimetostat 250 mg/daraxonrasib 100 mg), including one case of Grade 3 rash and one case of Grade 3 stomatitis and fatigue.

 •

 There were two dose reductions at dose level 1 and one dose reduction at dose level 2

 •

 There were no discontinuations due to adverse events

 Development strategy:
 Based on these data, Tango intends to
rapidly advance this combination approach into Phase 3 development for patients with MTAP-deleted pancreatic cancer. Subject to feedback from regulatory authorities, the Company plans to initiate a Phase 3
 randomized-controlled trial in front-line pancreatic cancer and evaluate opportunities to advance the second line combination towards registration phase.

 Vopimetostat plus zoldonrasib combination (PDAC with MTAP deletion and KRAS G12D mutation)

 In the vopimetostat plus zoldonrasib dose escalation arm, patients with PDAC received vopimetostat 200 mg or 250 mg QD plus zoldonrasib 600 mg or
1200 mg QD. As of the data cutoff date of May 28, 2026, 27 patients were response evaluable with at least 14 weeks of follow-up.

 Data highlights include:

 •

 52% ORR (14/27; 10 of 14 responses confirmed)

 •

 74% 6-month PFS rate

 •

 96% DCR

 •

 The vopimetostat plus zoldonrasib combination was generally well tolerated at all dose levels with no new
safety signals observed

 •

 Most adverse events were Grade 1 or 2. The most common TRAEs were nausea and vomiting.

 •

 There were no related Grade 4 or 5 adverse events

 •

 There were no DLTs

 •

 There was one dose reduction

 •

 There were no discontinuations due to adverse events

 Upcoming Anticipated Milestones

 •

 Finalize design of Phase 3 randomized-controlled trial of the combination
approach in front-line pancreatic cancer in 2H 2026

 •

 Disclose vopimetostat lung cancer monotherapy data in 2H 2026

 •

 Release initial TNG456 glioblastoma data 2H 2026

 •

 Present 2/3L PDAC vopimetostat + RAS(ON) inhibitors combination data at a scientific conference 2H 2026

 •

 Initiate Phase 1/2 vopimetostat + ERAS-0015 combination study 2H 2026

 Investor Webcast and Conference Call Information

 The Company will host a conference call to discuss these data at 8:00 a.m. ET today, June 8, 2026. The live webcast can be accessed under
“Events & Presentations” in the Investors section of the company’s website at www.tangotx.com. The webcast will be available for replay for at least 30 days on the company website. Analysts who wish to join the
teleconference and participate in Q&A should register here.
 About Vopimetostat

 Vopimetostat is a potentially best-in-class oral, once-daily, MTA-cooperative PRMT5 inhibitor that works selectively in cancer cells with MTAP (methylthioadenosine phosphorylase) deletion. MTAP deletions occur in 10-15% of all human
cancers, including approximately 40% of pancreatic cancer and 15% of lung cancer. Vopimetostat is being evaluated as monotherapy and in combination clinical studies. In ongoing clinical studies, vopimetostat has demonstrated a favorable safety and
tolerability profile to date and shown durable activity in multiple tumor types.
 About Tango Therapeutics

 Tango Therapeutics is a clinical-stage biotechnology company dedicated to discovering novel drug targets and delivering the next generation of precision
medicine for the treatment of cancer. Using an approach that starts and ends with patients, Tango leverages the genetic principle of synthetic lethality to discover and develop therapies that take aim at critical targets in cancer. For more
information, please visit www.tangotx.com.

 Forward-Looking Statements

 Certain statements in this press release may be considered forward-looking statements. All statements other than statements of historical fact are statements
that could be deemed forward-looking statements, including all statements regarding the intent, belief, or current expectation of Tango and members of the Tango senior management team. Forward-looking statements are not purely historical and may be
accompanied by words such as “may”, “should”, “expect”, “intend”, “plan”, “will”, “goal”, “estimate”, “anticipate”, “believe”,
“predict”, “designed,” “potential” or “continue”, or the negatives of these terms or variations of them or similar terminology. For example, implicit or explicit statements concerning the following
include or constitute forward-looking statements. Statements regarding: (i) the potential anticipated benefits, tolerability, efficacy and therapeutic profile of the Company’s PRMT5 inhibitors, as both standalone treatments and in
combination with RAS(ON)-inhibitors; (ii) the potential of vopimetostat to be a best-in-class PRMT5 inhibitor for the treatment of
 MTAP-del pancreatic and lung cancers; (iii) the Company’s development strategies and plans for vopimetostat, including ongoing and planned combination studies and potential advancement into Phase 3
development; (iv) the expected timing, design, conduct and results of current and future clinical trials, including clinical trial initiation, enrollment; and data disclosure; (v) the potential anticipated benefits, tolerability, efficacy
and therapeutic profile of the Company’s PRMT5 inhibitors, as both standalone treatments and in combination with RAS(ON)-inhibitors; (vi) the Company’s beliefs regarding the strength of the Phase 1/2 study data and the possibility
that such data may not be replicated in future studies. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such
forward-looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Tango and its management, are inherently uncertain. New risks and uncertainties may emerge from time to time,
and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to: the benefits of product candidates seen in preclinical tests and
analyses may not be evident when tested in later preclinical studies or in clinical trials or when used in broader patient populations (if approved for commercial sale); Tango has limited experience conducting clinical trials (and does and will
continue to rely on a third party to operate its clinical trials) and may not be able to commence or progress its clinical trials when expected, may not be able to continue dosing, initiate dose escalation and/or dose expansion on anticipated
timelines, and may not generate or report clinical trial results (including final, initial, interim, updated clinical trial results or additional safety and efficacy data and the establishment of proof-of-mechanism and proof-of-concept) in the anticipated timeframe (or at all); future clinical trial data releases may
differ materially from initial or interim data from our current and future clinical trials; Tango’s pipeline products may not be safe and/or effective in humans; Tango will need to raise capital in the future and if it is unable to raise
capital when needed or on attractive terms, it would be forced to delay, scale back or discontinue some of its development programs or future commercialization efforts (which may delay filing of INDs, dosing patients, initiation of dose expansion,
reporting clinical trial results and filing new drug applications); the expected benefits of Tango’s product candidates in patients as single agents and/or in combination may not be realized; Tango may experience delays or difficulties in the
initiation, enrollment, or dosing of patients in clinical trials or the announcement of clinical trial results; Tango’s product candidates may cause adverse or other undesirable side effects (or may not show requisite efficacy) that could,
among other things, delay or prevent regulatory approval; Tango’s dependence on one or a limited number third parties for conducting clinical trials and supplying and producing drug substance and drug product (including drug substance, which
is currently sole sourced); government regulation may negatively impact Tango’s business, including the potential approval of the BIOSECURE Act; the impact of trade restrictions such as sanctions or tariffs, legal actions or enforcement and
inflation rates on Tango’s business, financial condition, and results of operations; inadequate funding for or disruptions at the U.S. Food and Drug Administration or other government agencies may slow the time necessary for new drugs to be
reviewed and/or approved or prevent these agencies from performing business functions on which the operation of our business may rely (which could negatively impact its business). Additional information concerning risks, uncertainties and
assumptions can be found in Tango’s filings with the Securities and Exchange Commission (SEC), including the risk factors referenced in Tango’s Annual Report on Form 10-K for the fiscal year ended
December 31, 2025, as supplemented and/or modified by its most recent Quarterly Report on Form 10-Q. You should not place undue reliance on forward-looking statements in this press release, which speak
only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Tango specifically disclaims any duty to update these forward-looking statements.

 Investors:
 Elizabeth Hickin

 ehickin@tangotx.com
 Media:

 1AB
 Amanda Lazaro

 amanda@1abmedia.com

EX-99.2 · d158334dex992.htm

EX-99.2
 3
 d158334dex992.htm
 EX-99.2

 Exhibit 99.2 Vopimetostat and RAS(ON) combination data June 8,
2026

 Disclaimer and safe harbor statement Certain statements in this
presentation may be considered forward-looking statements. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including all statements regarding the intent, belief, or current
expectation of Tango and members of the Tango senior management team. Forward-looking statements are not purely historical and may be accompanied by terminology such as “may”, “should”, “expect”,
“intend”, “will”, “plan”, “path”, “achievable”, “milestones”, “goal”, “forecast”, “estimate”, “potential”,
“anticipate”, “believe”, “predict”, or “continue”, or the negatives of these terms or variations of them or similar terminology. For example, express or implied statements concerning the following
include or constitute forward- looking statements: the potential anticipated benefits, tolerability, efficacy and therapeutic profile of Tango's PRMT5 inhibitors, as both standalone treatments and in combination with RAS(ON)-inhibitors;
Tango’s belief that it has a competitive advantage; Tango’s regulatory plans and expectations, including its expectation that the combination of vopimetostat and RAS inhibitors could support a pivotal study in first line pancreatic
cancer and an innovative and fast path to first line approvals and accelerated second line approval; Tango’s expected cash runway; Tango’s plans for future trials, including combination trials, and the design, initiation and the release
of clinical data, and timing related thereto, for vopimetostat and TNG456, including with RAS(ON) inhibitors for vopimetostat; the expected benefits of the Company's development candidates and other product candidates (including for combination
studies); the Company’s expectations around the size and value of the potential patient population for PRMT5 inhibitors (including for lung and pancreatic cancers); potential combination strategies and uses for PRMT5 inhibitors, including
vopimetostat and TNG456; and the development and regulatory plans for the PRMT5 franchise. Such forward-looking statements are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those
expressed or implied by such forward looking statements. These forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Tango and its management at the time of this presentation, are inherently
uncertain. New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties. Factors that may cause actual results to differ materially from current expectations include, but are not limited to:
the benefits of product candidates seen in preclinical tests and analyses may not be evident when tested in later preclinical studies or in clinical trials or when used in broader patient populations (if approved for commercial sale); future
clinical trial data releases may differ materially from initial or interim data from our current and future clinical trials; Tango has limited experience with conducting clinical trials (and does and will rely on third parties to operate its
clinical trials) and may not be able to commence or progress its clinical trials when expected, may not be able to continue dosing, initiate dose escalation and/or dose expansion on anticipated timelines, and may not generate or report clinical
trial results (including final, initial, interim, updated clinical trial results or additional safety and efficacy data and the establishment of proof-of-mechanism and proof-of-concept) in the anticipated timeframe (or at all); Tango's pipeline
products may not be safe and/or effective in humans; Tango may utilize cash resources more quickly than anticipated; Tango will need to raise capital in the future and if it is unable to raise capital when needed or on attractive terms, Tango would
be forced to delay, reduce, or eliminate or discontinue some development programs or future commercialization efforts (which may delay filing of INDs, dosing patients, initiation of dose expansion, reporting clinical trial results and filing new
drug applications); the expected benefits of Tango’s product candidates in patients as single agents and/or in combination may not be realized; Tango may experience delays or difficulties in the initiation, enrollment, or dosing of patients in
clinical trials or the announcement of initial, interim, or final clinical trial results; Tango’s product candidates may cause adverse or other undesirable side effects (or may not show requisite efficacy) that could, among other things, delay
or prevent regulatory approval; Tango’s dependence on or a limited number third parties for conducting clinical trials and supplying and producing drug substance and drug product (including drug substance, which is currently sole sourced);
government regulation may negatively impact Tango's business, including the potential approval of the BIOSECURE Act; the impact of trade restrictions such as sanctions, tariffs, reciprocal and retaliatory tariffs, legal actions or enforcement and
inflation rates on our business, financial condition, and results of operations; inadequate funding for or disruptions at the U.S. Food and Drug Administration or other government agencies may slow the time necessary for new drugs to be reviewed
and/or approved or prevent these agencies from performing business functions on which the operation of our business may rely (which could negatively impact our business). Additional information concerning risks, uncertainties and assumptions can be
found in Tango’s filings with the SEC, including the risk factors referenced in Tango’s Annual Report on Form 10-K for the year ended December 31, 2025, as may be supplemented and/or modified by its most recent Quarterly Report on Form
10-Q. You should not place undue reliance on forward-looking statements in this presentation, which speak only as of the date they are made and are qualified in their entirety by reference to the cautionary statements herein. Tango specifically
disclaims any duty to update these forward- looking statements. Certain information contained in this Presentation relates to or is based on studies, publications, surveys and Tango’s own internal estimates and research. In addition, market
data included in this presentation involve assumptions and limitations, and there can be no guarantee as to the accuracy or reliability of such assumption. Finally, while Tango believe its internal research is reliable, such research has not been
verified by any independent source.

 Agenda for today Leader in PRMT5 targeted therapy for cancer Malte
Peters, MD | President and Chief Executive Officer Vopimetostat + RAS(ON) combination data show transformative potential in pancreatic cancer Brian Wolpin, MD | Dana-Farber Cancer Institute & Harvard Medical School Malte Peters, MD Brian Wolpin,
MD Strategy to accelerate registration-directed development of vopimetostat Adam Crystal, MD PhD | President of Research and Development Capital allocation plan and financial highlights Matthew Gall | Chief Financial Officer Closing remarks Malte
Peters, MD | President and Chief Executive Officer Adam Crystal, MD PhD Matthew Gall Q&A All 3

 Leader in PRMT5 targeted therapy for cancer Malte Peters, MD, President
and Chief Executive Officer 4

 At the forefront of transformative shift in pancreatic cancer treatment
Clear strategy Transformative Scientific leader for front line development 92% ORR in 2/3L PDAC in PRMT5 inhibition with chemotherapy free in combination with daraxonrasib regimen Near-term focus on potential blockbuster PDAC opportunity Pipeline
supporting data-driven indication expansion to drive long-term growth PDAC, pancreatic ductal adenocarcinoma; 2/3L, second/third line. Data from ongoing Phase 1/2 clinical trial. Data as of 28 May 2026. 5

 ~60,000 patients with MTAP del metastatic cancers annually in the US
Number of cases MTAP del % NSCLC 15% Plan to initially prioritize PDAC Pancreatic 40% GBM/glioma 45% • Potential blockbuster opportunity for Head and Neck 16% vopimetostat in PDAC alone Bladder 25% − Nearly all patients with an MTAP
deletion have a co-occurring KRAS mutation Breast 4% Uterine 14% − Significant medical need with potential for meaningful improvement over standard of care Melanoma 20% − Opportunity to lead in rapidly changing Gastric 14% landscape
Esophageal 22% • Multiple indication expansion opportunities Mesothelioma 31% (NSCLC, GBM) to drive long-term growth Ovarian 3% Renal 1% Prostate 1% Cholangio 10% 6 Patient population sizes estimated using data from SEER, Kantar, TCGA
PanCancer Atlas and other sources. PDAC, pancreatic ductal adenocarcinoma. NSCLC, non-small cell lung cancer.

 Brian Wolpin is a leader in the study and treatment of pancreatic cancer
v Professor of Medicine, Harvard Medical School v Robert T. & Judith B. Hale Chair in Pancreatic Cancer, Dana-Farber Cancer Institute v Director, Hale Family Center for Pancreatic Cancer Research and Gastrointestinal Cancer
Center, Dana-Farber Cancer Institute v Director, Dana-Farber – Lustgarten Foundation Dedicated Laboratory for Pancreatic Cancer Research v Medical oncologist with clinical specialty in pancreatic cancer v Research laboratory
dedicated to the investigation of pancreatic ductal adenocarcinoma (PDAC) biology and treatment 7

 Vopimetostat + RAS(ON) combination data show transformative potential in
pancreatic cancer Dr. Brian Wolpin, MD, MPH Dana-Farber Cancer Institute & Harvard Medical School 8

 Evolution of standard of care for pancreatic cancer RAS INHIBITORS + 1
CHEMOTHERAPY RAS INHIBITORS PRMT5 INHIBITORS Current standard; Improved response Increased response rate and Limited efficacy and durability prolonged durability Today Emerging Potential Next Generation 1. Wolpin et al. ASCO, 2026. 9

 Vopimetostat selectively inhibits the cell essential gene PRMT5 in MTAP
deleted cancer cells deletion causes MTA accumulation only in cancer cells X MTAP X MTA MTA partially inhibits PRMT5 activates PRMT5 MTA MTA SAM by replacing SAM in normal cells Vopimetostat PRMT5 inhibits PRMT5 only in MTAP-del cancer cells when
MTA is bound 10

 PRMT5 + RAS inhibition demonstrated preclinical synergy In vivo model
demonstrated striking combination efficacy Key points G12D MTAP-null, KRAS PDAC CDX (KP4) • KRAS inhibition + PRMT5 inhibition is synergistic in 1 multiple preclinical models • Clinical data to date support synergy of combination in
patients Days on Study Day 28 on Treatment 100 mpk QD 20 mpk QD RMC-9805 + Vehicle RMC-9805 BID TNG462 TNG462 1. Knoll, Cancer Research 2025; Drizyte-Miller, Cancer Research 2025 PDAC, pancreatic ductal adenocarcinoma; QD, once daily; BID, twice
daily. 11

 Vopimetostat + panRAS inhibition may yield maximal synergy panRAS
inhibition may result in maximal synergy G12D specific inhibition may allow partial rescue by wtRAS Compensatory vopimetostat daraxonrasib vopimetostat zoldonrasib wtRAS Signaling RAS KRAS G12D wtRAS PRMT5 PRMT5 Disrupted Disrupted Decreased
Decreased Maintains arginine arginine MAPK signaling MAPK signaling MAPK signaling methylation methylation Submaximal synergy Synergy Cancer Discovery. 2020;10(4): 556–569. Ryan MB, Fece de la Cruz F, Phat S, et al. Cell Reports.
2022;39(2):110993. Feng H, et al. Oncogene. 2023;42: 1–13. Wang X, et al. Pathology & Oncology Research. 2024;30:1611948. 12

 First PRMT5 inhibitor combined with RAS inhibitors in the clinic Phase
1 dose escalation trial Vopimetostat + daraxonrasib: • Dose escalation range: vopimetostat Any RAS mut 200 mg – 250 mg vopimetostat QD + daraxonrasib + 100 mg daraxonrasib QD 2L+ MTAP-del/ RAS mut pancreatic • Evaluable patients
and lung cancer vopimetostat + Safety n=25 G12D mut zoldonrasib Efficacy n=15 Key inclusion criteria: • MTAP loss by NGS or IHC MTAP status for enrollment: • 1-2 lines prior systemic therapy in metastatic setting 85% by NGS / 15% by IHC
• ECOG PS 0 or 1 • No prior PRMT5i or RASi ~95% concordance (NGS and IHC) Data extract 28 May 2026. Patients who received first dose at least 14 weeks prior to data cutoff were efficacy evaluable. All treated patients were safety
evaluable. 2L, second line; NGS, next-generation sequencing; IHC, immunohistochemistry. 13

 Patient baseline characteristics vopimetostat + vopimetostat +
Vopimetostat + daraxonrasib daraxonrasib zoldonrasib (PDAC) (NSCLC) (PDAC) N 20 5 34 Sex, male, n (%) 9 (45) 3 (60) 18 (53) Age, years, median (range) 66 (46-74) 55 (38-71) 66 (37-81) Number of prior lines of systemic therapy in metastatic setting,
n (%) 0 1 (5)* - - 1 6 (30) 1 (20) 15 (44) 2 13 (65) 3 (60) 19 (56) 3 - 1 (20) - Median number of prior lines of systemic therapy in 2 2 2 metastatic setting Patients with liver metastatic disease, n (%) 14 (70) 1 (20) 26 (77) ECOG, n (%) 0 12 (60)
2 (40) 9 (26) 1 8 (40) 3 (60) 25 (74) Data extract 28 May 2026. One patient treated with vopimetostat + daraxonrasib (PDAC) withdrew consent in cycle 1. *Patient was not candidate for chemotherapy and enrolled according to protocol. PDAC, pancreatic
ductal adenocarcinoma; NSCLC, non-small cell lung cancer. 14

 Vopimetostat + daraxonrasib in MTAPdel 2/3L PDAC: ORR 92% - 11 PRs in
12 patients 20 Line of therapy: N=12 2 2 2 3 3 2 3 3 3 3 1 2 ORR 92% 0 DL1 DL1 DL1 DL1 DL1 DL1 DL1 DL2 DL1 DL2 DL1 DL2 DCR 100% -20 * • 9 cPR • 2 uPR pending confirmation -40 Best Objective Response: -60 ■ Partial Response (PR)
■ Stable Disease (SD) -80 Ongoing Therapy -100 Dose levels: DL1: 200 mg vopimetostat + 100 mg daraxonrasib DL2: 250 mg vopimetostat + 100 mg daraxonrasib Data extract 28 May 2026. Dashed line indicates threshold for PR (-30%). Objective
response rate per RECIST v1.1 includes patients who received first dose of the study drug at least 14 weeks prior to the data extract to allow for 2 post-baseline scans. Median duration of follow-up 6.8 months (3.3 - 9.7). *Patient discontinued due
to non-compliance. Disease control rate (DCR) defined as fraction of patients with overall response of SD, PR, or CR at the time of the first scheduled scan. PDAC, pancreatic ductal adenocarcinoma; ORR, objective response rate; DCR, disease control
rate; 2/3L, second/third line. 15 Best Overall Response (%)

 Vopimetostat + daraxonrasib in MTAPdel NSCLC and PDAC: ORR 93% - 14 PRs
in 15 patients 20.0 Line of therapy: N=15 2 2 2 3 3 2 4 3 3 3 3 3 1 3 2 .0 ORR 93% DL1 DL1 DL1 DL1 DL1 DL1 DL1 DL1 DL2 DL1 DL1 DL2 DL1 DL1 DL2 DCR 100% -20.0 * • 12 cPR • 2 uPR pending confirmation -40.0 Dose level and indication: -60.0
■ DL1, PDAC ■ DL2, PDAC -80.0 ■ DL1, NSCLC Ongoing Therapy -100.0 Dose levels: DL1: 200 mg vopimetostat + 100 mg daraxonrasib DL2: 250 mg vopimetostat + 100 mg daraxonrasib Data extract 28 May 2026. Dashed line indicates threshold
for PR (-30%). Objective response rate (ORR per RECIST v1.1) and all efficacy data is reported in patients who received their first dose of the study drug combination at least 14 weeks prior to the data extract to allow for 2 potential post-baseline
scans. Median duration of follow-up 6.7 months (3.3 - 9.7). *Patient discontinued due to non-compliance. Disease control rate (DCR) defined as fraction of patients with overall response of SD, or PR at the time of the first evaluation. PDAC,
pancreatic ductal adenocarcinoma; NSCLC, non-small cell lung cancer. ORR, objective response rate; DCR, disease control rate; 2/3L, second/third line. 16 Best Overall Response (%)

 Encouraging durability with vopimetostat + daraxonrasib Line of
Indication therapy PDAC3 Key Metrics NSCLC3 PDAC3 • Two disease progressions 3 PDAC observed PDAC2 • Longest treatment ~10 PDAC3 months, ongoing 3 PDAC PDAC2 • Median PFS NR (NE-NE) ∗ PDAC2 • 90% 6-month PFS rate in
PDAC2 PDAC (95% CI: 47-99) Best Overall Response: PDAC3 • 50% of PDAC patients are 3L ■ Partial Response (PR) PDAC1 ■ Stable Disease (SD) 4 NSCLC • Patients not yet efficacy Ongoing Therapy * NSCLC3 evaluable (n=9) are all
Disease Progression PDAC2 ongoing with no disease progression 0 1 2 3 4 5 6 7 8 9 10 Dose levels: Months DL1: 200 mg vopimetostat + 100 mg daraxonrasib DL2: 250 mg vopimetostat + 100 mg daraxonrasib Data extract 28 May 2026. The swimmer plot
displays all patients who received their first dose of the study drug combination at least 14 weeks prior to the data extract to allow for 2 potential post-baseline scans. ∗Patient discontinued due to non-compliance. PDAC, pancreatic ductal
adenocarcinoma. NSCLC, non-small cell ling cancer. CI, 17 confidence interval.

 72 year old woman with MTAPdel, KRAS-G12R metastatic pancreatic cancer
who received vopimetostat + daraxonrasib in the 3L setting Cycle 7, day 1: Baseline cPR (-52%) Response ongoing Data extract 28 May 2026. 3L, third line; cPR, confirmed partial response. 18

 Vopimetostat + daraxonrasib was generally well tolerated Dose level 1
Dose level 1 Dose level 2 Safety Summary 200 mg vopimetostat + 200 mg vopimetostat + 250 mg vopimetostat + 100 mg daraxonrasib 100 mg daraxonrasib 100 mg daraxonrasib • No new safety signals observed PDAC, N=16 NSCLC, N=5 PDAC, N=4 • No
discontinuations due to AEs • Two dose reductions – dose level 1 All grades Grade 3 All grades Grade 3 All grades Grade 3 • One dose reduction – dose level 2 TRAEs ≥15% • Most AEs were Grade 1 or 2 Patients with
any event 12 (75) 4 (25) 5 (100) - 4 (100) 3 (75) • No related Grade 4 or 5 AEs Rash* 7 (44) - 5 (100) - 4 (100) 1 (25) • No related SAEs Diarrhea 5 (31) - 4 (80) - 3 (75) - • At dose level 1: No DLTs Stomatitis/mucositis 9 (56) -
1 (20) - 1 (25) 1 (25) • At dose level 2: Fatigue 2 (13) - 1 (20) - 3 (75) 1 (25) • DLTs in 2 patients: Thrombocytopenia 4 (25) 2 (13) 1 (20) - 1 (25) - • Grade 3 acneiform rash (dose Nausea 2 (13) - 2 (40) - 1 (25) - reduced,
continued on study) Peripheral edema 2 (13) - - - 2 (50) - • Grade 3 stomatitis and fatigue (withdrew consent) Plan to advance dose level 1 into further clinical development Data extract 28 May 2026. The safety population includes all patients
with PDAC who received at least one dose of the study drug combination prior to the data extract. Median duration of follow-up 5.8 (1.0-9.7). *Rash includes TRAEs of rash, rash maculo-papular and dermatitis acneiform. DLT, dose-limiting toxicity.
SAE, serious adverse event. TRAE, treatment-related adverse event. 19

 Vopimetostat + daraxonrasib has favorable RAS associated safety profile
vopimetostat 200 mg + daraxonrasib 100 mg (PDAC and lung) Pharmacokinetics and safety n=21 (TRAEs, % patients) dose level 1 • Daraxonrasib AUC: 4106 hr*ng/ml (n=13, CV Rash 40.5%) 1 Stomatitis/Mucositis - Similar to daraxonrasib 300 mg single
agent • PRMT5 inhibition may improve RAS inhibitor- Diarrhea mediated on target toxicity due to upregulation 2 of MAPK activation / pERK Nausea • No grade ≥ 3 RAS associated TRAEs Fatigue Vomiting ■ Grade 1-2 Paronychia 0%
20% 40% 60% 80% 100% Median follow-up: 5.0 months Data extract 28 May 2026. Data displayed are AEs most frequently associated with RAS inhibitors. There were no Grade 3+ related AEs. 1. Wolpin et al, NEJM, N Engl J Med 2026;394:1790-1802. 2. Knoll,
Cancer Research 2025; Drizyte-Miller, Cancer Research 2025

 First PRMT5 inhibitor combined with RAS inhibitors in the clinic
Vopimetostat + zoldonrasib: Phase 1 dose escalation trial • Dose escalation range: vopimetostat Any RAS mut 200 – 250 mg vopimetostat QD + + daraxonrasib 2L+ MTAP-del/ 600 – 1200 mg zoldonrasib QD RAS mut pancreatic and lung cancer
• Evaluable patients: vopimetostat + Safety n=34 G12D mut zoldonrasib Efficacy n=27 Key inclusion criteria: MTAP status for enrollment: • MTAP loss by NGS or IHC • Prior lines: 85% by NGS / 15% by IHC − PDAC: 1-2 lines prior
systemic therapy in metastatic setting ~95% concordance (NGS and IHC) • ECOG PS 0 or 1 • No prior PRMT5i or RASi Data extract 28 May 2026. Patients who received first dose at least 14 weeks prior to data cutoff were efficacy evaluable,
all treated patients safety evaluable. 2L, second line; NGS, next-generation sequencing; IHC, immunohistochemistry; PDAC, pancreatic ductal adenocarcinoma; NSCLC, non-small cell lung cancer. 21

 Vopimetostat + zoldonrasib was generally well tolerated Safety Summary
All dose levels vopimetostat + • No new safety signals observed zoldonrasib N=34 • No discontinuations due to AEs All grades Grade 3 • One dose reduction TRAEs ≥15% • Most AEs were Grade 1 or 2 Patients with any event
28 (82) 9 (26) • No related Grade 4 or 5 AEs Anemia 8 (24) 6 (18) • 3 treatment related SAEs Nausea 12 (35) - • Anemia Vomiting 12 (35) - • Thrombocytopenia Rash (all grade 1) 8 (24) - • Vision blurred Diarrhea 7 (21) 1
(3) • No DLTs Fatigue 7 (21) - Dysgeusia 6 (18) - Data extract 28 May 2026. Safety-evaluable population includes patients who received at least 1 dose of the study drug combination. There were no related Grade 4 or 5 events. Median duration of
follow-up 4.9 months (0.6-11.1). TRAE, treatment-related adverse event; SAE, serious adverse event; DLT, dose-limiting toxicity. 22

 Vopimetostat + zoldonrasib in MTAPdel KRAS G12D 2/3L PDAC: ORR 52% - 14
PRs in 27 patients 20 Line of therapy: 3 3 3 3 3 3 3 3 3 3 2 2 3 2 3 2 3 2 3 3 3 2 2 3 2 3 2 DL1 0 DL3 DL2 DL2 DL2 DL3 DL1 DL4 DL2 DL1 DL3 DL2 DL1 DL3 DL2 DL1 DL1 DL1 DL2 DL1 DL1 DL2 DL4 DL1 DL1 DL1 DL1 N=27 -20 ORR 52% DCR 96% -40 • 10 cPR
• 4 uPR pending confirmation Best Overall Response: -60 ■ Complete response (CR) • 74% 6-month PFS rate (95% ■ Partial Response (PR) CI: 49-88) ■ Stable Disease (SD) -80 ■ Progressive Disease (PD) Ongoing Therapy
-100 DL DL2 DL2 DL2 DL1 DL2 DL1 DL1 DL1 DL2 DL1 DL1 DL1 DL2 DL1 DL1 DL1 Dose levels: DL1: 200 mg vopimetostat + 600 mg zoldonrasib LoT 3 3 2 3 3 3 3 2 3 3 3 2 2 2 3 2 DL2: 250 mg vopimetostat + 600 mg zoldonrasib DL3: 250 mg vopimetostat + 1200 mg
zoldonrasib DL4: 200 mg vopimetostat + 1200 mg zoldonrasib Data extract 28 May 2026. Dashed line indicates threshold for PR (-30%). Objective response rate (ORR) is reported in patients who received their first dose at least 14 weeks prior to the
data extract to allow for 2 potential post-baseline scans. ORR includes patients with PR or CR that has been confirmed (n=10) or is pending confirmation (n=4). Median follow-up 5.6 months (3.3-11.1). DCR, disease control rate, defined as fraction of
patients with overall response of stable disease or better at the time of the first scheduled on-treatment evaluation (6 weeks). TRAE, treatment-related adverse event. DLT, dose-limiting toxicity. SAE, serious adverse event, CI, confidence interval.
Best Overall Response (%)

 Combined ORR 64% in 2/3L PDAC demonstrates clinical synergy of
vopimetostat + RAS(ON) inhibition N=39 20 ORR 64% PD 0 DCR 97% SD SD SD -20 SD SD SD SD SD SD SD PR PR PR PR PR PR -40 PR SD PR PR SD SD PR PR PR PR PR PR PR PR PR PR -60 PR PR Vopimetostat + zoldonrasib, PDAC PR -80 PR ■ Vopimetostat +
daraxonrasib, PDAC Ongoing therapy PR -100 CR Data extract 28 May 2026. Dashed line indicates threshold for PR. Objective response rate (ORR) is reported in PDAC patients who received their first dose of the study drug combination at least 14 weeks
prior to the data extract to allow for 2 potential post-baseline scans. Median follow-up 6.3 months (3.3 - 11.1). DCR, disease control rate, defined as fraction of patients with overall response of stable disease or better at the time of the first
scheduled on-treatment evaluation (6 weeks). PDAC, pancreatic ductal adenocarcinoma. 24 Best Overall Response (%)

 Strategy to accelerate registration-directed development of
vopimetostat Adam Crystal, MD PhD, President of Research and Development 25

 Tango's strategy to potentially develop vopimetostat + daraxonrasib
combination for patients with pancreatic cancer Assess contribution of components 1 Expansion of Primary Phase 1/2 study Readout Explore accelerated 2L approval 2 Primary 1L approval 1L RCT 3 Readout Plan to engage global regulatory authorities to
share Phase 1/2 data and discuss registration strategy Subject to regulatory feedback. 1L, first line; 2L, second line; RCT, randomized controlled trial. 26

 Capital allocation plan and financial highlights Matthew Gall, Chief
Financial Officer 27

 Disciplined capital allocation focused on most promising,
value-creating opportunities Multiple inflection points anticipated Clear path forward by end of 2026 q Finalize design of Phase 3 randomized-controlled trial Rapidly advance 1L PDAC vopimetostat + of the combination approach in front-line
pancreatic daraxonrasib chemo-free combination cancer in 2H 2026 q Disclose vopimetostat lung cancer monotx data 2H Accelerate PRMT5 assets to near-term value- inflecting milestones with capital efficiency q Release initial TNG456
glioblastoma data 2H q Present 2/3L PDAC vopimetostat + RAS(ON) inhibitors Optimize robust monotherapy and combination combination data to a scientific conference 2H PRMT5 franchise across multiple indications q Initiate Phase 1/2
vopimetostat + ERAS-0015 combination study 2H $380M cash and investments as of March 31, 2026 Cash runway into 2028 PDAC, pancreatic ductal adenocarcinoma. 28

 Closing remarks Malte Peters, MD, Chief Executive Officer 29

 At the forefront of transformative shift in pancreatic cancer treatment
Clear strategy Transformative Scientific leader for front line development 92% ORR in 2/3L PDAC in PRMT5 inhibition with chemotherapy free in combination with daraxonrasib regimen Near-term focus on potential blockbuster PDAC opportunity Pipeline
supporting data-driven indication expansion to drive long-term growth PDAC, pancreatic ductal adenocarcinoma; 2/3L, second/third line. Data from ongoing Phase 1/2 clinical trial. Data as of 28 May 2026. 30

 CONFIDENTIAL